S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
NASDAQ:OPNT

Opiant Pharmaceuticals - OPNT Stock Forecast, Price & News

Add
Compare
Today's Range
N/A
50-Day Range
$20.03
▼
$21.10
52-Week Range
N/A
Volume
562,700 shs
Average Volume
77,920 shs
Market Capitalization
$108.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

OPNT stock logo

About Opiant Pharmaceuticals (NASDAQ:OPNT) Stock

Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.

Receive OPNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Opiant Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

OPNT Stock News Headlines

March 3, 2023 | msn.com
Indivior Acquires Opiant Pharmaceuticals Strengthening Its Addiction Treatment And Science Portfolio
February 22, 2023 | finance.yahoo.com
Opiant Pharmaceuticals, Inc.'s (NASDAQ:OPNT) largest shareholders are individual investors with 52% ownership, institutions own 33%
March 24, 2023 | Stansberry Research (Ad)
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
February 7, 2023 | finance.yahoo.com
Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC
January 26, 2023 | seekingalpha.com
Horizon Pharma, Opiant fall amid Elizabeth Warren concern about pharma deals (update)
January 19, 2023 | finance.yahoo.com
Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose
January 13, 2023 | seekingalpha.com
Opiant Pharmaceuticals: Nano-Cap Buyout With Interesting CVR Thrown In
January 7, 2023 | businesswire.com
OPIANT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Opiant ...
March 24, 2023 | Stansberry Research (Ad)
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
November 22, 2022 | finance.yahoo.com
Opiant Pharmaceuticals Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose
November 15, 2022 | benzinga.com
OPNT Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of Opiant Pharmaceuticals
November 15, 2022 | benzinga.com
EQUITY ALERT: The M&A Class Action Firm Announces the Investigation of Opiant Pharmaceuticals, Inc. - OPNT
November 14, 2022 | benzinga.com
Shareholder Alert: Ademi LLP investigates whether Opiant Pharmaceuticals Inc. has obtained a Fair Price in its transaction with Indivior
November 14, 2022 | benzinga.com
OPNT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Opiant Pharmaceuticals, Inc. Is Fair to Shareholders
November 14, 2022 | nasdaq.com
Indivior To Buy Opiant For $145 Mln In Cash
November 14, 2022 | seekingalpha.com
Opiant surges 123% as Indivior set to acquire overdose therapy maker for $145M
November 14, 2022 | marketwatch.com
Opiant Pharmaceuticals Shares Surge Premarket on Takeover by Indivior >OPNT
November 14, 2022 | finance.yahoo.com
Indivior PLC to Acquire Opiant Pharmaceuticals
November 14, 2022 | finance.yahoo.com
Opiant Pharmaceuticals Announces Third Quarter 2022 Financial Results
November 14, 2022 | finance.yahoo.com
Narcan Owner Opiant to Be Acquired by Indivior for $145 Million
November 2, 2022 | finance.yahoo.com
The past five years for Opiant Pharmaceuticals (NASDAQ:OPNT) investors has not been profitable
October 27, 2022 | finance.yahoo.com
Opiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022
October 6, 2022 | finance.yahoo.com
Opiant Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OPNT002, Nasal Naltrexone, in Patients with Alcohol Use Disorder
October 5, 2022 | marketwatch.com
INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Opiant Pharmaceuticals, Inc. for Potential Breach of Fiduciary Duty Claims
August 22, 2022 | finance.yahoo.com
Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering OPNT004 for the Treatment of Cannabinoid Hyperemesis Syndrome
August 13, 2022 | finance.yahoo.com
Analysts Just Shaved Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts Dramatically
August 11, 2022 | finance.yahoo.com
Opiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate Update
See More Headlines
Receive OPNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Opiant Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

OPNT Company Calendar

Last Earnings
11/11/2021
Today
3/24/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OPNT
CUSIP
N/A
CIK
1108924
Web
www.opiant.com
Phone
(310) 598-5410
Fax
917-322-2105
Employees
37
Year Founded
2009

Profitability

EPS (Most Recent Fiscal Year)
($6.56)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$3.01 million
Net Margins
-147.90%
Pretax Margin
-147.84%
Return on Equity
-97.03%
Return on Assets
-59.66%

Debt

Debt-to-Equity Ratio
0.60
Current Ratio
5.48
Quick Ratio
5.48

Sales & Book Value

Annual Sales
$47.78 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
24.75
Book Value
$9.92 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
5,270,000
Free Float
3,865,000
Market Cap
$108.83 million
Optionable
Not Optionable
Beta
0.84

Social Links


Key Executives

  • Roger CrystalRoger Crystal
    President, Chief Executive Officer & Director
  • David D. O'TooleDavid D. O'Toole
    Chief Financial Officer & Secretary
  • Phil SkolnickPhil Skolnick
    Chief Scientific Officer
  • Mark Jason H. Ellison
    Chief Development Officer
  • Matthew R. RuthMatthew R. Ruth
    Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













OPNT Stock - Frequently Asked Questions

Should I buy or sell Opiant Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opiant Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" OPNT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OPNT, but not buy additional shares or sell existing shares.
View OPNT analyst ratings or view top-rated stocks.

How were Opiant Pharmaceuticals' earnings last quarter?

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) posted its quarterly earnings results on Thursday, November, 11th. The technology company reported $0.56 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.15 by $0.41. The technology company earned $16.34 million during the quarter, compared to analysts' expectations of $12.45 million. Opiant Pharmaceuticals had a negative trailing twelve-month return on equity of 97.03% and a negative net margin of 147.90%. During the same quarter in the prior year, the company posted $0.15 EPS.

What other stocks do shareholders of Opiant Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Opiant Pharmaceuticals investors own include Cara Therapeutics (CARA), AcelRx Pharmaceuticals (ACRX), Sangamo Therapeutics (SGMO), Synchrony Financial (SYF), Vodafone Group Public (VOD), Agenus (AGEN), Aldeyra Therapeutics (ALDX), Aurinia Pharmaceuticals (AUPH), Corbus Pharmaceuticals (CRBP) and CyberArk Software (CYBR).

What is Opiant Pharmaceuticals' stock symbol?

Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT."

Who are Opiant Pharmaceuticals' major shareholders?

Opiant Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Western Standard LLC (8.22%), Morgan Stanley (3.83%), Renaissance Technologies LLC (2.84%), Wells Fargo & Company MN (2.65%), Dimensional Fund Advisors LP (1.94%) and New York Life Investment Management LLC (1.20%). Insiders that own company stock include Brian Gorman, Craig A Collard, Craig A Collard, David D O'toole, Gabrielle Alison Silver, Mark Jason Heath Ellison, Matthew R Ruth, Michael Sinclair, Phil Skolnick, Roger Crystal and Thomas T Thomas.
View institutional ownership trends.

How do I buy shares of Opiant Pharmaceuticals?

Shares of OPNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How much money does Opiant Pharmaceuticals make?

Opiant Pharmaceuticals (NASDAQ:OPNT) has a market capitalization of $0.00 and generates $47.78 million in revenue each year. The technology company earns $3.01 million in net income (profit) each year or ($6.56) on an earnings per share basis.

How can I contact Opiant Pharmaceuticals?

Opiant Pharmaceuticals' mailing address is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. The official website for the company is www.opiant.com. The technology company can be reached via phone at (310) 598-5410, via email at investor.relations@opiant.com, or via fax at 917-322-2105.

This page (NASDAQ:OPNT) was last updated on 3/24/2023 by MarketBeat.com Staff